Daniel J. Deangelo

Q: What Schools Are Affiliated With Daniel J. Deangelo

Daniel J. Deangelo is affiliated with the following schools: University of Alberta

Daniel J. Deangelo's AcademicInfluence.com Rankings

Daniel J. Deangelo

Philosophy

#8788

World Rank

#12235

Historical Rank

Logic

#5806

World Rank

#7246

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Daniel J. Deangelo's Degrees

Doctorate Medicine Harvard University

Why Is Daniel J. Deangelo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daniel J. Deangelo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. (2003) (1709)
Acute lymphoblastic leukemia. (2019) (1383)
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia (2006) (1325)
Differentiation and reversal of malignant changes in colon cancer through PPARγ (1998) (1071)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017) (1021)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (2016) (882)
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. (2013) (878)
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (2009) (773)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005) (696)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. (2015) (652)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy (2011) (521)
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. (2014) (513)
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. (2010) (464)
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. (2009) (384)
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia (2009) (321)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML (2012) (316)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. (2018) (309)
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. (2004) (301)
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. (2003) (299)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. (2006) (259)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia (2012) (256)
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms (2018) (255)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. (2007) (244)
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. (2003) (234)
Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia (2014) (232)
A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. (2006) (231)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (213)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. (2006) (212)
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. (2018) (206)
Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation (2007) (199)
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. (2014) (198)
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel (2011) (192)
Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study (2015) (186)
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. (2006) (186)
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. (2014) (185)
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. (2007) (185)
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease (2010) (181)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (2019) (177)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study (2019) (176)
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. (2004) (172)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study (2021) (163)
Proteomic and genetic approaches identify Syk as an AML target. (2009) (162)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission (2016) (158)
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. (2007) (151)
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. (2017) (145)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
A precision therapy against cancers driven by KIT/PDGFRA mutations (2017) (137)
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. (2007) (134)
SYK is a critical regulator of FLT3 in acute myeloid leukemia. (2014) (134)
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. (2010) (133)
Gefitinib induces myeloid differentiation of acute myeloid leukemia. (2005) (133)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies (2013) (124)
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions (2016) (120)
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. (2013) (113)
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. (2018) (113)
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia (2008) (112)
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. (2010) (111)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia (2017) (107)
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. (2012) (103)
Targeting MTHFD2 in acute myeloid leukemia (2015) (103)
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. (2013) (103)
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (2015) (98)
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2020) (98)
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. (2017) (97)
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. (2004) (96)
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia (2012) (95)
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). (2009) (94)
Alu elements mediate MYB gene tandem duplication in human T-ALL (2007) (94)
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry (2013) (93)
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies (2014) (93)
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. (2013) (91)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results (2018) (90)
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma (2009) (88)
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial (2018) (86)
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Review (2018) (86)
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. (2015) (84)
The treatment of adolescents and young adults with acute lymphoblastic leukemia. (2005) (83)
A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets (2013) (81)
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema (2018) (79)
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms (2021) (77)
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. (2016) (76)
Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines (2013) (76)
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. (2010) (75)
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial (2015) (72)
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia (2017) (72)
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. (2005) (70)
Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remission (2016) (67)
A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia (2014) (66)
Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia (2018) (65)
Novel SSBP2‐JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia (2008) (65)
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. (2018) (64)
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer (2011) (64)
Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation (2004) (64)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis (2013) (64)
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. (2018) (63)
Chronic myelogenous leukemia, version 1.2015. (2014) (61)
A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. (2006) (60)
Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation (2011) (60)
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. (2017) (59)
Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia (2014) (59)
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) (2005) (59)
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial (2012) (58)
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia (2008) (58)
Fatal hepatic necrosis following imatinib mesylate therapy. (2003) (57)
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) (2016) (56)
KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial (2010) (56)
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts (2020) (55)
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. (2021) (55)
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials (2011) (53)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (53)
SYK Regulates mTOR Signaling in AML (2013) (53)
Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial (2014) (53)
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. (2017) (53)
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. (2017) (53)
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. (2019) (53)
The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. (2005) (52)
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. (2009) (52)
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021) (51)
Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. (2008) (51)
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. (2018) (50)
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. (2019) (50)
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers (2018) (50)
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. (2010) (49)
Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. (2019) (48)
Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case (2015) (48)
The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling (2014) (48)
Identification of AML1-ETO modulators by chemical genomics. (2009) (48)
Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia (2018) (47)
Acute Lymphoblastic Leukemia, Version 2.2015. (2015) (47)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts (2017) (46)
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes (2003) (46)
Acute lymphoblastic leukemia: Clinical practice guidelines in oncology (2012) (45)
Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia. (2009) (44)
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE (2018) (43)
A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma (2015) (42)
Chronic Myelogenous Leukemia, Version 1.2014. (2013) (42)
Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. (2017) (41)
Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML) (2016) (41)
Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML) (2014) (40)
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. (2014) (39)
Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. (2004) (38)
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review (2018) (37)
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2019) (36)
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy (2019) (36)
The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial (2014) (36)
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. (2009) (35)
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia (2015) (34)
A forgotten cause of kidney injury in chronic myelomonocytic leukemia. (2009) (34)
A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial (2015) (33)
The embryonic enhancer-binding protein SSAP contains a novel DNA-binding domain which has homology to several RNA-binding proteins (1995) (33)
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. (2016) (33)
Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. (2005) (33)
A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis (2010) (33)
Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM) (2017) (32)
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. (2009) (32)
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804 (2009) (32)
A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results (2019) (31)
The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia (2018) (31)
Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies (2005) (31)
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies (2018) (31)
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. (2008) (30)
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes (2017) (30)
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study (2018) (30)
Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma (2014) (29)
Ponatinib‐induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities (2015) (29)
A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML) (2015) (29)
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial (2021) (28)
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). (2020) (28)
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (2012) (27)
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. (2019) (27)
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia (2020) (27)
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 (2012) (27)
Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia (2015) (27)
Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. (2007) (26)
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial (2021) (26)
Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 (2013) (26)
Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML) (2016) (26)
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. (2014) (26)
Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. (2015) (25)
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy (2012) (25)
De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study (2014) (25)
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden (2020) (25)
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy (2016) (25)
A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage (2014) (24)
Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL) (2012) (24)
A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia (2019) (24)
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy (2015) (24)
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. (2002) (23)
SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML (2015) (23)
Treatment of young adults with Philadelphia‐negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper‐CVAD vs. pediatric‐inspired regimens (2018) (23)
Insulin receptor substrate 1 is a substrate of the Pim protein kinases (2016) (23)
An embryonic enhancer determines the temporal activation of a sea urchin late H1 gene (1989) (23)
The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy (2015) (23)
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia (2016) (22)
Low dose interleukin‐2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission (2008) (22)
PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED >= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPY (2016) (22)
Recent Advances in Managing Acute Lymphoblastic Leukemia. (2020) (22)
RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. (2015) (21)
Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML). (2006) (21)
PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation (2013) (21)
The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial. (2007) (21)
Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses (2018) (20)
Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia (2018) (20)
Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy (2019) (19)
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice (2010) (19)
The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH (2020) (19)
Current challenges and opportunities in treating adult patients with Philadelphia‐negative acute lymphoblastic leukaemia (2017) (19)
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes (2022) (19)
Single cell RNA-seq reveals developmental plasticity with coexisting oncogenic and immune evasion programs in ETP-ALL. (2020) (19)
Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines (2019) (18)
Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance (2013) (18)
The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. (2015) (18)
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor (2021) (18)
Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib. (2013) (18)
Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. (2013) (17)
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected (2018) (17)
A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma (2013) (17)
Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies. (2007) (17)
Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia (2001) (17)
Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. (2016) (16)
A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. (2004) (16)
Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations (2010) (16)
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice (2017) (16)
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. (2019) (16)
Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (2012) (16)
Detecting T-cell reactivity to whole cell vaccines (2012) (15)
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia (2021) (15)
Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis. (2009) (15)
Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (2016) (15)
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (2017) (15)
Purification and characterization of the stage-specific embryonic enhancer-binding protein SSAP-1 (1993) (15)
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2020) (15)
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies (2015) (14)
Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial (2012) (14)
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma (2020) (14)
Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay (2015) (14)
Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy (2002) (14)
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison (2015) (14)
Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. (2013) (13)
Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. (2005) (13)
Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial (2013) (13)
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. (2021) (13)
Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous Leukemia (2015) (13)
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. (2019) (13)
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia. (2019) (13)
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia (2018) (13)
An asymptomatic 61‐year‐old man with BCR‐ABL‐positive bone marrow following autologous transplantation for multiple myeloma (2010) (13)
The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study (2010) (13)
Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts (2014) (12)
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. (2015) (12)
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial (2015) (11)
Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience. (2008) (11)
Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic (2020) (11)
ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial (2016) (11)
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) (2012) (11)
Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. (2017) (11)
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. (2011) (11)
Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial (2013) (11)
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome (2021) (11)
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia (2021) (10)
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Myeloid Leukemia, Version 2.2021 (2020) (10)
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). (2018) (10)
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? (2016) (10)
The clinical and functional effects of TERT variants in myelodysplastic syndrome. (2021) (10)
Is the cryptic interstitial deletion of 8q24 surrounding MYC a common mechanism in the formation of double minute chromosome? (2005) (10)
Chronic myelogenous leukemia. (2020) (10)
Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study (2019) (10)
Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD (2011) (10)
Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia. (2008) (10)
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active (2021) (10)
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial (2018) (10)
Imatinib Therapy for Patients with Chronic Myelogenous Leukemia (2004) (9)
Phase I Dose Escalating Trial of Bortezomib (Velcade®) in Combination with Idarubicin and Cytarabine in Patients with Acute Myeloid Leukemia. (2004) (9)
Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update (2011) (9)
Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease (2018) (9)
Systemic mastocytosis: current classification and novel therapeutic options. (2006) (9)
Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. (2008) (9)
GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML. (2017) (9)
PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. (2012) (9)
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin (2019) (9)
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (2019) (9)
Acute lymphoblastic leukemia and lymphoblastic lymphoma (2013) (9)
GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study (2017) (9)
Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome. (2022) (9)
Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial (2012) (9)
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 (2021) (9)
Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study (2015) (9)
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy (2015) (9)
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re‐induction chemotherapy (2019) (8)
Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients (2013) (8)
Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML. (2004) (8)
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials (2021) (8)
Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (2011) (8)
Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia (2018) (8)
Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis (2020) (8)
Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues (2017) (8)
A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML). (2014) (8)
A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). (2009) (8)
Posttransplant Immunotherapy with a GM-CSF-Based Tumor Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) for Acute Myeloid Leukemia (AML). (2004) (8)
Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study (2020) (8)
Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML) (2020) (8)
Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advancedTP53wt acute leukemias (2017) (8)
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
Screens, iron, and leukemia. (2009) (7)
A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies (2010) (7)
A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults (2021) (7)
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. (2003) (7)
Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings (2020) (7)
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission (2019) (7)
Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (2012) (7)
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee (2022) (7)
Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase (2013) (7)
Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in JAK2-mutant myeloproliferative neoplasms (2020) (7)
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database (2020) (7)
Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201+A2213) In Patients With Advanced Systemic Mastocytosis Compared With Historical Controls (2017) (7)
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. (2020) (7)
S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) (2019) (7)
Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials (2021) (7)
GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML. (2017) (7)
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis. (2014) (6)
Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. (2016) (6)
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study (2019) (6)
Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib. (2009) (6)
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials (2020) (6)
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis (2022) (6)
Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT) (2005) (6)
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling (2019) (6)
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan (2019) (6)
Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study (2017) (6)
A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia. (2009) (6)
A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis. (2010) (6)
DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions (2015) (6)
Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML) (2019) (6)
A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date (2016) (6)
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial (2021) (5)
Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs) (2013) (5)
A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults (2019) (5)
Phase II Study of VNP40101M (Cloretazine®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML). (2007) (5)
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. (2018) (5)
Brain natriuretic peptide level as marker of cardiac function in imatinib — treated chronic myeloid leukemia patients : no evidence of cardiotoxicity of imatinib therapy (2008) (5)
Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials (2018) (5)
Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML (2004) (5)
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms (2020) (5)
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy (2022) (5)
Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) (2013) (5)
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy (2020) (5)
Avapritinib for Advanced Systemic Mastocytosis. (2022) (5)
Single 6-mg dose of rasburicase: The experience in a large academic medical center (2018) (5)
Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial. (2016) (5)
Resistance revealed in acute lymphoblastic leukemia (2013) (5)
Hairy cell leukemia presenting as a palpable breast mass (2014) (5)
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib (2017) (5)
How to treat chronic myeloid leukemia (CML) in older adults. (2018) (5)
Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leu (2020) (5)
Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia (2019) (4)
A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (2020) (4)
A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML) (2012) (4)
Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results. (2006) (4)
Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis (2020) (4)
Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission (2011) (4)
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level (2017) (4)
Posttransplant immunotherapy with a GM-CSF-based tumor vaccine following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML). (2004) (4)
Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd (2019) (4)
Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia (2015) (4)
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia. (2020) (4)
Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results (2019) (4)
Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML). (2006) (4)
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. (2012) (4)
Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia. (2017) (4)
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin (2020) (4)
Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant? (2020) (4)
S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS (2022) (4)
Clinical Trial Evaluating DC/AML Fusion Cell Vaccination in AML Patients Who Achieve a Chemotherapy-Induced Remission (2014) (4)
Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2017) (4)
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021 (2021) (4)
FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML) (2016) (3)
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia. (2011) (3)
Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study (2021) (3)
Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. (2020) (3)
A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM) (2021) (3)
Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit (2015) (3)
Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy (2019) (3)
A Pilot Trial of Rapamycin with Glucocorticoids In Children and Adults with Relapsed ALL (2010) (3)
Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (2019) (3)
T‐cell acute lymphoblastic leukemia: Current approach and future directions (2019) (3)
Perceptions of Prognosis and Treatment Risk in Older Patients with Acute Myeloid Leukemia (2017) (3)
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? (2016) (3)
A Phase II study of VNP40101M in elderly patients (pts) with de novo poor risk acute myelogenous leukemia (AML) (2008) (3)
Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration (2017) (3)
BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia (2013) (3)
When to go FISHing. (2010) (3)
Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia (AML). (2017) (3)
A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML) (2008) (3)
Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results (2019) (3)
A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. (2020) (3)
Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (2017) (3)
New agents for the treatment of patients with acute lymphoblastic leukemia (2008) (3)
Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study (2017) (3)
Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. (2015) (3)
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories (2019) (3)
A Novel CSF3R Activating Mutation Identified in a Patient with Chronic Neutrophilic Leukemia (2021) (3)
Gefitinib (Iressa) induces myeloid differentiation of acute myeloid leukemia (2005) (3)
A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML). (2006) (3)
Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (2010) (3)
Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study (2010) (3)
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2021) (2)
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies (2019) (2)
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%). (2018) (2)
A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2021) (2)
Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib (2010) (2)
Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study (2015) (2)
P1049: A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS (2022) (2)
Quality of life and psychological distress in patients with acute myeloid leukemia (AML). (2018) (2)
Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase (2016) (2)
MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies (2021) (2)
Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (2)
Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2018) (2)
Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic (2021) (2)
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis (2022) (2)
Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM) (2010) (2)
Role of Imatinib-Sensitive Tyrosine Kinases in the Pathogenesis of Chronic Myeloproliferative Disorders (2007) (2)
Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation (2018) (2)
Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (2020) (2)
Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation. (2006) (2)
Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium (2014) (2)
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax (2022) (2)
Ponatinib in Heavily Pretreated Leukemia: 3-Year PACE Trial Results (2015) (2)
A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) (2021) (2)
High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS. (2004) (2)
transplantation (ASCT) as postremission therapy for acute myeloid cellular immunotherapy in combination with autologous stem cell secreting - Granulocyte-macrophage colony-stimulating factor (GM-CSF) (2013) (2)
ORIGINAL ARTICLE On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia (2008) (2)
Abstract 3516: AZD1208 PIM kinase inhibitor - Preliminary evidence of target pathway inhibition in Phase I clinical trials of AML. (2013) (2)
Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM) (2021) (2)
Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation (2016) (2)
Predictive Factors for All-Trans Retinoic Acid Related Differentiation Syndrome In Acute Promyelocytic Leukemia. (2010) (2)
QoL of pediatric-inspired compared to hyper-CVAD regimens for newly diagnosed AYA patients with Ph-ALL: A modeling analysis. (2017) (2)
Acute Lymphoblastic Leukemia, Version 2.2021 (2021) (2)
Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy (2021) (2)
The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols. (2009) (2)
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (2019) (1)
Chronic Myeloid Leukemia , Version 1 . 2017 Featured Updates to the NCCN Guidelines (1)
Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML) (2005) (1)
Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study (2021) (1)
Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations (2019) (1)
A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia (2015) (1)
Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation (2014) (1)
Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia (2016) (1)
Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells (2014) (1)
Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia (2013) (1)
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity (2021) (1)
Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia (2017) (1)
Time from randomization to first subsequent induction/salvage therapy (ST) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. (2019) (1)
Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML (2015) (1)
Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin (2018) (1)
respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3 (2013) (1)
Pretreatment clinical and genetic factors predict early post‐treatment mortality in fit AML patients following induction (2021) (1)
Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients (2011) (1)
Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia (2019) (1)
Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML) (2018) (1)
Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study (2018) (1)
More or Less? Impact of Dose Number on Outcomes of Patients with Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin (2019) (1)
Looking Under the Hood of Early T-Cell Precursor Acute Lymphoblastic Leukemia (2012) (1)
Induction Therapy of Acute Myeloid Leukemia (2011) (1)
Geﬁtinib induces myeloid differentiation of acute myeloid leukemia (2005) (1)
Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone (2015) (1)
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib. (2018) (1)
Abstract CT147: Phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors (2016) (1)
Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML (2015) (1)
Hematology and Oncology (2014) (1)
PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN (2022) (1)
Patient-Reported Outcomes Associated with Different Treatments for Myelodysplastic Syndromes (2016) (1)
Chronic Myeloid Leukemia , Version 1 . 2019 Clinical Practice Guidelines in Oncology (2018) (1)
Factors associated with allogeneic hematopoietic stem cell transplantation (HSCT) outcomes in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO) versus (v) conventional chemotherapy (C). (2017) (1)
CML-121: Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs) (2020) (1)
Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial. (2018) (1)
A t(4;12)(q11;p13) in a patient with coincident CLL at the same time of AML diagnosis (2011) (0)
A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). (2010) (0)
mpact of Conditioning Regimen Intensity n Outcome of Allogeneic Hematopoietic Cell ransplantation for Advanced Acute Myelogenous eukemia and Myelodysplastic Syndrome (2006) (0)
Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells (2015) (0)
P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML (2022) (0)
PS954 TIME FROM RANDOMIZATION TO FIRST SUBSEQUENT INDUCTION/SALVAGE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN IN THE PHASE 3 INO-VATE TRIAL (2019) (0)
P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE (2022) (0)
age hematopoietic cell transplantation for patients older than 50 years of Comparative outcome of nonmyeloablative and myeloablative allogeneic (2013) (0)
Outcome of adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols, 1991-2000. (2006) (0)
CML-109: Exploratory Biomarker Analysis from ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) from Poor Response in Chronic Myeloid Leukemia (CML) (2020) (0)
Flow cytometry minimal residual disease assessment in peripheral blood of adult acute lymphoblastic leukemia patients. (2017) (0)
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee (2022) (0)
HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase (2013) (0)
Bacillus Cereus: A Leukemia-Specific, Neuroinvasive Pathogen? (2014) (0)
P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 (2022) (0)
Mitochondrial DNA Mutations Distinguish Individual Donor- and Recipient-Derived Immune Cells Following Matched Unrelated Allogeneic Stem Cell Transplantation (2021) (0)
Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study (2018) (0)
P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES (2022) (0)
Prospective Cohort Study of Geriatric Assessment in Older Patients with Acute Myeloid Leukemia (2012) (0)
166 Safety of panobinostat plus 5-azacitidine in myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia patients: a phase Ib study (2011) (0)
Identification of CKMT1B As a New Target in EVI1-Positive AML (2015) (0)
Analysis of Healthcare Professional Management of CAR T-Cell Toxicities and Concordance with Expert Consensus Recommendations (2022) (0)
Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3α (GSK-3α) as a Modulator of Differentiation In Acute Myeloid Leukemia (2010) (0)
Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center (2015) (0)
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. (2012) (0)
Prediction of Life-threatening and Disabling Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (2021) (0)
Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). (2015) (0)
pharmacodynamics myelodysplastic syndrome: safety, pharmacokinetics, and antagonist, in patients with acute myelogenous leukemia or high-risk Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 (2013) (0)
stem cell transplantation veno-occlusive disease in patients who undergo myeloablative allogeneic Prior gemtuzumab ozogamicin exposure significantly increases the risk of (2013) (0)
Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach (2013) (0)
Comprar Chronic Myelogenous Leukemia, An Issue of Hematology/Oncology Clinics of North America | Daniel DeAngelo | 9781437725308 | Saunders (2011) (0)
Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function. (2006) (0)
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies (2019) (0)
Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation (2019) (0)
hematologic malignancies After chronic myelogenous leukemia: tyrosine kinase inhibitors in other (2013) (0)
Geriatric Assessment Variables Add Prognostic Value to the International Prognostic Scoring System (2012) (0)
Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML. (2005) (0)
Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax (2021) (0)
Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hematologic malignancies at high or potential risk for tumor lysis syndrome (2008) (0)
Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies (2020) (0)
CML-089: Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia (2020) (0)
Treatment of Relapsed Acute Lymphoblastic Leukemia (2011) (0)
Abstract B10: Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia. (2015) (0)
SOLVING CLINICAL PROBLEMS IN BLOOD DISEASES An asymptomatic 61-year-old man with BCR-ABL -positive bone marrow following autologous transplantation for multiple myeloma (2010) (0)
1033PQuantitative assessment of inotuzumab ozogamicin (InO) response relative to investigator’s choice of chemotherapy (ICC) in adults with relapsed or refractory (R/R) CD22+ B-Cell acute lymphoblastic leukemia (ALL) (2017) (0)
IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels (2014) (0)
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123-Positive Hematologic Malignancies (2019) (0)
Jerome Ritz Leukemia : Are Patients Living Longer ? Imatinib Therapy for Patients with Chronic Myelogenous (2004) (0)
Clinical problem-solving. A joint venture. (2008) (0)
Systematic KIT Sequencing Identifies Unsuspected Systemic Mastocytosis with Associated Hematological Neoplasm (2017) (0)
Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL (2019) (0)
Bring Novel Agents to the Fore in B-ALL: Adding Inotuzumab to Pediatric-Inspired Regimens for AYAs (2018) (0)
Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial (2022) (0)
Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis. (2012) (0)
Enasidenib in mutant relapsed or refractory acute myeloid leukemia. (2017) (0)
655 Concordance between healthcare providers and expert consensus recommendations in the management, monitoring, and mitigation of adverse events associated with CAR T-cell therapy: an updated analysis (2020) (0)
Impact of sleep disturbance in myelodysplastic syndromes (MDS). (2015) (0)
P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY (2022) (0)
AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC). (2022) (0)
The NCCN Guidelines and the following discussions focus on the immunophenotypic classification and cytogenetic / molecular subtypes of ALL , risk assessment and stratification for risk-adapted therapy , treatment strategies for Philadelphia chro-NCCN Acute Lymphoblastic Leukemia Clinical Practice Gu (2012) (0)
Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols (2021) (0)
Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status (2010) (0)
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia (2022) (0)
A Retrospective Review Comparing Outcomes of Patients Receiving Reinduction Therapy on House Staff and PA Services (2013) (0)
Chronic myelogenous leukemia. Preface. (2011) (0)
Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia (2016) (0)
Switching drugs midstream for patients with chronic myeloid leukemia. (2014) (0)
PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (2022) (0)
Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML) (2018) (0)
lymphoma: Cancer and Leukemia Group B study 19801 refractory T-lineage acute lymphoblastic leukemia or lymphoblastic Nelarabine induces complete remissions in adults with relapsed or (2013) (0)
Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients < 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD (2010) (0)
PKC412 Inhibits the ZNF198-FGFR1 Fusion Tyrosine Kinase and Is Efficacious in Treatment of t(8;13)(p11;q12) Associated Stem Cell Myeloproliferative Disease. (2004) (0)
Triona Ni Chonghaile Response to Cytotoxic Chemotherapy Pretreatment Mitochondrial Priming Correlates with Clinical (2011) (0)
Acknowledgement to Reviewers (2012) (0)
Low Efficacy and High Mortality Associated with Clofarabine Treatment of Patients with Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes (2014) (0)
Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML) (2015) (0)
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers (2018) (0)
Subgroup Analyses of Kte-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Adult Patients (Pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in Zuma-3 (2023) (0)
Refractory Anemia With Excess Blasts In Transformation (Acute Myeloid Leukemia with 20-29% Blasts) in Older Adults is Less Aggressive Than Acute Myeloid Leukemia With ≥30% Blasts (2013) (0)
Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study (2021) (0)
A new case of isolated del(12)(q15q22) in myelodysplastic syndrome. (2001) (0)
Management of T‐Cell Acute Lymphoblastic Leukemia (2014) (0)
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. (2022) (0)
ASH 2012 Update on ACUTE LEUKEMIA (2012) (0)
JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations. (2007) (0)
Ontogeny-Specific Patterns of Genetic Alterations in Acute Myeloid Leukemia (2014) (0)
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? (2021) (0)
Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine. (2016) (0)
Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index (2011) (0)
Racial and ethnic enrollment disparities in acute myeloid leukemia clinical trials. (2021) (0)
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in myeloproliferative neoplasm patients. (2021) (0)
Clinical Impact of an Internet-Based Tool to Help Guide Therapeutic Changes While Monitoring Patients with Chronic Myeloid Leukemia Receiving First-Line Tyrosine Kinase Inhibitor Therapy (2012) (0)
Outcomes for Older Patients with Acute Myeloid Leukemia after Admission to the Intensive Care Unit (ICU) (2018) (0)
Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) (2018) (0)
Acute Lymphoblastic LeukemiaPractice Guidelines in Oncology (2012) (0)
A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia, the DFCI Experience (2009) (0)
AGenome-WideAberrantRNASplicing inPatientswithAcute MyeloidLeukemia IdentifiesNovelPotentialDiseaseMarkers and Therapeutic Targets (2014) (0)
Efficacy and Safety of Inotuzumab Ozogamicin in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated in the INO-VATE Trial: Outcomes by Salvage-Treatment Phase (2019) (0)
FLT3 Tyrosine Kinase in AML Identification and Characterization of a Novel Activating Mutation of the (2012) (0)
A Distributed International Patient Data Registry for Hairy Cell Leukemia (2016) (0)
Impact of Operator Techniques On Quality of Bone Marrow Assessment (2012) (0)
Local Mate Competition Experimental Evolution of Reduced Sex Ratio Adjustment Under (2011) (0)
The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia (2013) (0)
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission. (2019) (0)
Chronic Myelogenous LeukemiaPractice Guidelines in Oncology TM (2009) (0)
PS949 INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION (2019) (0)
19 AN OBJECTIVE GENETIC ONTOGENY CLASSIFICATION IDENTIFIES TRUE BIOLOGICAL SECONDARY AML AMONG DE NOVO AML PATIENTS ≥60 YEARS OLD (2015) (0)
Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors (2013) (0)
RECQL 5 Suppresses Onco genic JAK 2-Induced Replication Stress and Genomic Instability Graphical (2015) (0)
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (2021) (0)
P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY (2022) (0)
A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia (2015) (0)
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. (2022) (0)
has homology to several RNA-binding proteins . contains a novel DNA-binding domain which The embryonic enhancer-binding protein SSAP (1995) (0)
Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Daniel J. Deangelo?

Daniel J. Deangelo is affiliated with the following schools:

University of Alberta